This finding indicates that various cancer therapies, including immune checkpoint blockade and cell-based immunotherapies, can be enhanced by supplementation of this inhibitor into the treatment regimens, as not only will it drive EGFR inhibition, decreasing cancer growth, but it will also drive degradation of PD-L1, enhancing anti-tumor immunity. This evidence concerns the gene CD274 and cancer.